Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

PrognosDx to collaborate with MMRI on cancer tests
August 2013
SHARING OPTIONS:

PALO ALTO, Calif.A broad sponsored collaborative research and development agreement was signed in early July between PrognosDx Health Inc. and the Molecular Medicine Research Institute (MMRI), providing state-of-the-art laboratory resources for PrognosDx to launch CLIA laboratory services, including a prostate cancer prognosis test and predictive tests for other cancers. The agreement also establishes a platform for introductions to select pharma partners to develop a new class of epigenetic therapeutics based on recent discoveries by PrognosDx's scientific founders. Initially, the collaboration will focus on treating hormone refractory prostate cancer with PrognosDx's global histone modification-based biomarkers and cellular metabolism-related therapeutic insight. MMRI will perform clinical sample analyses and preclinical studies using PrognosDx's biomarkers, and additional planned projects include collaboration with an academic center on breast and gastrointestinal cancers.    

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.